An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure

Gian Marco Rosa, Simone Ferrero, Paola Ghione, Alberto Valbusa, Claudio Brunelli

Research output: Contribution to journalArticle

Abstract

Introduction: Ivabradine is a new heart-rate-lowering drug; the aim of this review was to analyze its role in heart failure (HF). Areas covered: This systematic review on the role of ivabradine in HF is based on material searched and obtained through Pubmed and Medline up to September 2013. Expert opinion: Heart rate (HR) is a risk factor in patients with HF, and its reduction is considered an important goal of therapy. The BEAUTIFUL trial demonstrated the benefits of ivabradine on prognosis (only on ischemic endpoints) in patients with coronary artery disease (CAD) and left ventricular systolic dysfunction (LVSD) and HR ≥ 60 bpm. In the SHIFT trial, which enrolled patients with LVSD, HF and HR ≥ 70 bpm, ivabradine administration (on top of guideline-based therapy, including β-blockers [BB]) was associated with a reduction of cardiovascular death and hospitalizations for HF, but BB were underutilized. Further studies are needed to test the efficacy of ivabradine in CAD patients with high HR and to shed light on the comparison between ivabradine and a more aggressive therapy with higher doses of BB in HF patients.

Original languageEnglish
Pages (from-to)279-291
Number of pages13
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume10
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

ivabradine
Pharmacodynamics
Pharmacokinetics
Treatment Failure
Heart Failure
Heart Rate
Left Ventricular Dysfunction
Coronary Artery Disease
Systolic Heart Failure
Expert Testimony
PubMed
Hospitalization
Therapeutics
Guidelines

Keywords

  • Coronary artery disease
  • Heart failure
  • Ivabradine

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure. / Rosa, Gian Marco; Ferrero, Simone; Ghione, Paola; Valbusa, Alberto; Brunelli, Claudio.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, No. 2, 02.2014, p. 279-291.

Research output: Contribution to journalArticle

Rosa, Gian Marco ; Ferrero, Simone ; Ghione, Paola ; Valbusa, Alberto ; Brunelli, Claudio. / An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure. In: Expert Opinion on Drug Metabolism and Toxicology. 2014 ; Vol. 10, No. 2. pp. 279-291.
@article{964b4433265a47d7b2f3d1683bd59349,
title = "An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure",
abstract = "Introduction: Ivabradine is a new heart-rate-lowering drug; the aim of this review was to analyze its role in heart failure (HF). Areas covered: This systematic review on the role of ivabradine in HF is based on material searched and obtained through Pubmed and Medline up to September 2013. Expert opinion: Heart rate (HR) is a risk factor in patients with HF, and its reduction is considered an important goal of therapy. The BEAUTIFUL trial demonstrated the benefits of ivabradine on prognosis (only on ischemic endpoints) in patients with coronary artery disease (CAD) and left ventricular systolic dysfunction (LVSD) and HR ≥ 60 bpm. In the SHIFT trial, which enrolled patients with LVSD, HF and HR ≥ 70 bpm, ivabradine administration (on top of guideline-based therapy, including β-blockers [BB]) was associated with a reduction of cardiovascular death and hospitalizations for HF, but BB were underutilized. Further studies are needed to test the efficacy of ivabradine in CAD patients with high HR and to shed light on the comparison between ivabradine and a more aggressive therapy with higher doses of BB in HF patients.",
keywords = "Coronary artery disease, Heart failure, Ivabradine",
author = "Rosa, {Gian Marco} and Simone Ferrero and Paola Ghione and Alberto Valbusa and Claudio Brunelli",
year = "2014",
month = "2",
doi = "10.1517/17425255.2014.876005",
language = "English",
volume = "10",
pages = "279--291",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure

AU - Rosa, Gian Marco

AU - Ferrero, Simone

AU - Ghione, Paola

AU - Valbusa, Alberto

AU - Brunelli, Claudio

PY - 2014/2

Y1 - 2014/2

N2 - Introduction: Ivabradine is a new heart-rate-lowering drug; the aim of this review was to analyze its role in heart failure (HF). Areas covered: This systematic review on the role of ivabradine in HF is based on material searched and obtained through Pubmed and Medline up to September 2013. Expert opinion: Heart rate (HR) is a risk factor in patients with HF, and its reduction is considered an important goal of therapy. The BEAUTIFUL trial demonstrated the benefits of ivabradine on prognosis (only on ischemic endpoints) in patients with coronary artery disease (CAD) and left ventricular systolic dysfunction (LVSD) and HR ≥ 60 bpm. In the SHIFT trial, which enrolled patients with LVSD, HF and HR ≥ 70 bpm, ivabradine administration (on top of guideline-based therapy, including β-blockers [BB]) was associated with a reduction of cardiovascular death and hospitalizations for HF, but BB were underutilized. Further studies are needed to test the efficacy of ivabradine in CAD patients with high HR and to shed light on the comparison between ivabradine and a more aggressive therapy with higher doses of BB in HF patients.

AB - Introduction: Ivabradine is a new heart-rate-lowering drug; the aim of this review was to analyze its role in heart failure (HF). Areas covered: This systematic review on the role of ivabradine in HF is based on material searched and obtained through Pubmed and Medline up to September 2013. Expert opinion: Heart rate (HR) is a risk factor in patients with HF, and its reduction is considered an important goal of therapy. The BEAUTIFUL trial demonstrated the benefits of ivabradine on prognosis (only on ischemic endpoints) in patients with coronary artery disease (CAD) and left ventricular systolic dysfunction (LVSD) and HR ≥ 60 bpm. In the SHIFT trial, which enrolled patients with LVSD, HF and HR ≥ 70 bpm, ivabradine administration (on top of guideline-based therapy, including β-blockers [BB]) was associated with a reduction of cardiovascular death and hospitalizations for HF, but BB were underutilized. Further studies are needed to test the efficacy of ivabradine in CAD patients with high HR and to shed light on the comparison between ivabradine and a more aggressive therapy with higher doses of BB in HF patients.

KW - Coronary artery disease

KW - Heart failure

KW - Ivabradine

UR - http://www.scopus.com/inward/record.url?scp=84892753699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892753699&partnerID=8YFLogxK

U2 - 10.1517/17425255.2014.876005

DO - 10.1517/17425255.2014.876005

M3 - Article

C2 - 24377458

AN - SCOPUS:84892753699

VL - 10

SP - 279

EP - 291

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 2

ER -